Kenneth L. Rinehart, Jr.
The end of a legend...the beginning of a legacy

Kenneth L. Rinehart, Jr., the chemistry professor at the University of Illinois at Urbana-Champaign who was internationally known for his research on organic compounds involved in biological activity, will continually be remembered for his outstanding research in the field of natural products & marine chemistry.

Ken’s life will always be a beaming light to all who knew him.

This Summer special issue is dedicated to the fond memories of Dr. Kenneth L. Rinehart, Jr.

Norman Farnsworth Honored...

ASP Research Achievement Award-2005

This year the American Society of Pharmacognosy (ASP) has selected Dr. Norman R. Farnsworth of Univ. of Illinois at Chicago, to honor him with the prestigious ASP Research Achievement Award - 2005, for his lifelong contributions to the field of pharmacognosy. He is also a Founding Member & the Second President of the Society (1961-62).

The award will be presented to Dr. Farnsworth at the ASP Annual Meeting in Corvallis, OR during the banquet ceremony.

Continued on page 7...
Dear Friends,

Greetings!

The summer 2005 issue brings another successful year for the ASP Newsletter to an end. It is the time to look back on our achievements and plan for the future. As we look back we find that although our scientific community has explored new dimensions in many areas of natural products research, but we have lost several renowned scientists in the last few years. And now the news of the demise of Dr. Rinehart was so heart breaking. With sadness in my heart I write this editorial to pay tribute to one of the giants of Natural Products & Marine Chemistry, ... Professor Kenneth L. Rinehart, Jr. To the ASP and the scientific community, it is a great loss. We cherish the memory of a leading scientist, a great scholar and, above all, a friend of ASP.

Dr Rinehart was a mentor, an advisor and a friend to me. Reminiscing of my association with Dr. Rinehart, I vividly remember the summer of 1982 when he asked me to join the Frederick Cancer Research Facility in Frederick, MD. His words still echo in my ears: “Frederick needs you more than I. There is a challenge waiting for you and I know you can solve it.” Thus, I joined the National Cancer Institute (NCI) and received the honor / credit for solving the unique x-ray crystal structure of anticancer antibiotic – Freidricamycin-A. I owe this to Dr. Rinehart. I will miss him dearly.

This is a special issue dedicated to the memory of Prof. Rinehart. It contains a few glimpses from his past and several other important and timely items: ASP honors Prof. Farnsworth with Research Achievement Award 2005; Outstanding achievements of some of our ASP members; New ASP members and exciting news items in various segments. Also included is an elaborate report on the workshop “Classical Pharmacognosy Forum: The Critical Need for Pharmacognosy in Pharmacy Curricula,” organized at ICNPR-2004 in Phoenix, Arizona.

The time for our next annual meeting at Corvallis, OR is just around the corner. This is a great opportunity to meet old friends, make new one’s and celebrate our achievements as we accept new challenges.

It is gratifying that we received several encouraging letters with positive comments from the readers about the substance, format, appearance and news items. We are grateful for the kind words of appreciation. I also express my gratitude to all those who have shown their faith in me with this responsibility as the Editor of the Newsletter, especially (late) Bill Pelletier, David Slatkin, Bob Krueger, Doug Kinghorn, Jon Clardy, and others. Thank you all!

Please continue to send your feedback and news about your achievements, recognition and awards, etc. We always love to hear from you.

Have a safe and enjoyable summer!

Renuka
Winners of 2004 Schwarting & Beal Awards...

For Best Papers in the Journal of Natural Products

In 2001, the Foundation Board of American Society of Pharmacognosy began a new initiative as a result of the Arthur E. Schwarting and Jack L. Beal Awards for the best papers in the Journal of Natural Products. In this manner, two former distinguished editors of the journal are fondly remembered. These awards are funded through the American Society of Pharmacognosy Foundation Board.

The Schwarting Award is open to all papers published in the journal within a given year (either in print or electronically). In turn, the Beal Award is awarded to younger investigators [i.e., persons within 12 years of receiving their Ph.D. degree or within 10 years of gaining their first professional appointment (e.g., Assistant Professor or an equivalent position in industry or government)]. A two-tier process was used to determine the winners, the winners for papers published in Journal of Natural Products in 2004, with editors Daneil Ferreira, William H. Gerwick, A. Douglass Kinghorn, and Richard G. Powell having nominated two papers each for the Schwarting Award and one paper each for the Beal Award. ASP President Jim McAlpine appointed an ad hoc committee (John Rosazza, Chair, Ben Shen, Yuzuru Shimizu) to make the final selections. The winners are as follows (the asterisks * denote the corresponding authors & winners):

A 2004 Arthur E. Schwarting Award

**WINNER:** Sheo B. Singh*

Nodulisporic acids D-F: Structure, biological activities, and biogenetic relationships.

Sheo B. Singh*, John G. Ondeyka, Hiranthi Jayasuriya, Deborah L. Zink, Sookhee N. Ha, Arlene Dahl-Roshak, Joyce Greene, Jennifer A Kim, Mc Hardy M. Smith, Wesley Shoop, and Jan S. Tkacz


B 2004 Jack L. Beal Award

**WINNER:**

Yu-Dong Zhou* & Dale G. Nagle*

Laurenditerpenol, a new diterpene from the tropical marine alga Laurencia intricata that potently inhibits HIF-1 mediated hypoxic signaling in breast tumor cells.

Khaleem A. Mchammed, Choudhary F. Hossain, Lei Zhang, Richard L. Bruick, Yu-Dong Zhou* and Dale G. Nagle*


The corresponding authors of these papers will be invited to attend the Banquet at the 46th Annual Meeting of the ASP in Corvallis, OR to receive a check and a plaque in honor of their achievement.

The above-mentioned papers may be accessed from the home page of the Journal of Natural Products (http://pubs.acs.org/JNP).

Congratulations to the winners of these prestigious awards!
A Warm Welcome to New....

FULL MEMBERS

Martha L. Gay
FDA/CFSAN
College Park, MD

Xiaojing Ma
Tucson, AZ

Shawngela F. Pierce
Norfolk, VA

Michael M. McCoy
Falcon Foam
Grand Rapids, MI

Jinfeng Hu
Sequoia Sciences, Inc.
San Diego, CA

Minglei Wang
Florida Int. University
Miami, FL

Robert J. McGivney
RTI International
Clayton, NC

Zhong-mei Zou
Mt. Sinai Sch. of Med.
New York, NY

Venkata S. Pullela
Univ. of Mississippi
University, MS

Steven R. King
PS Pharma, Inc.
S. San Francisco, CA

Silvia R. da Costa
Buena Park, CA

Peter Zhang
Shaklee Corp.
Hayward, CA

Sharnelle S. Phifer
RTI International
Durham, NC

Rama Rao Manam
Nereus Pharm. Inc.
San Diego, CA

M. Verbitski
ChromaDex Analytics
Arvada, CO

Goede Schueller
DSM Nut. Products
Basel, Switzerland

Bambang P. EW
Airlangga Univ.
Surabaya, Indonesia

Allison McCutcheon
U. of British Columbia
Vancouver, Canada

Richard Martin
L’Oreal
Notre Dame d’Oe’, France

Wandee Gritsanapan
Dept. of Pharmacog.
Mahidol University
Bangkok, Thailand

Nasir Sultana
BCSIR Laboratories
Dhaka, Bangladesh

Kan He
Pure World Bot., Inc.
South Hackensack, NJ

Priyadarshini Raman
Xechem, Inc.
New Brunswick, NJ

Hannah N. Sivak
Gilbert, AZ

Lyle E. Craker
Dep. of Plant & Soil Sc.,
Univ. of Massachusetts
Amherst, MA

William A. Soderlund
Soderlund Village Drug
Saint Peter, MN

Jennifer L. Gu
AIDP, Inc.
City of Industry, CA

W. Dennis Clark
Arizona State Univ.
Tempe, AZ

D. K. Sharma
Univ. of Pittsburgh
Pittsburgh, PA

Tianzhu JIA
Liaoning Coll. of Trad.
Chinese Med. & Herbs
Shenyang, China

Gabriel Fontana
Indena SpA
Milan, Italy

Paride Cavaggli
Magenta, Italy

Olomewoju Omobuwajo
O. A. Univ. Nigeria
Dusseldorf, Germany

Chungsook Kim
Yuseong-gu, Korea

Kolo Ibrahim
Garki-Abuja, Nigeria

Orisadipe Ayabomi T.
Nat. I. Pharm. Res.
Dev.
Idu-Abuja, Nigeria

Helikki Vuorela
Univ. of Helsinki
Helsinki, Finland

Raimo Hiltunen
Univ. of Helsinki
Helsinki, Finland

Joe Sodipo
Surulere, Nigeria

Prashanth Kumar V.
Ahmedabad, India

Pierre Tane
University of Dschang
Dschang, Cameroon

Quanbo Xiong
Rice University
Houston, TX

Betsy B. Singh
Xechem, Inc.
New Brunswick, NJ

John Krstenansky
Loma Linda Univ.
Loma Linda, CA

David Fast
Ada, MI

Jiangnan Peng
University, MS

ASP is looking forward to your participation in....
you at the 46th Annual Meeting at....
<table>
<thead>
<tr>
<th>Name</th>
<th>University/City</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Geeta Watal</td>
<td>Medicinal Res. Lab. Allahabad, India</td>
<td></td>
</tr>
<tr>
<td>Eme U. Ekaette</td>
<td>Abuja, Nigeria</td>
<td></td>
</tr>
<tr>
<td>Rivero Isabel</td>
<td>Mexico City, Mexico</td>
<td></td>
</tr>
<tr>
<td>Rivero Blanca</td>
<td>Mexico City, Mexico</td>
<td></td>
</tr>
<tr>
<td>Joelle Quein-Leclercq</td>
<td>Catholic U. of Louvain Bruxelles, Belgium</td>
<td></td>
</tr>
<tr>
<td>Ahmed A. Taha</td>
<td>Univ. of Bahrain</td>
<td></td>
</tr>
<tr>
<td>Corinne Girard</td>
<td>U. de Franche Comte Besncon, France</td>
<td></td>
</tr>
<tr>
<td>Ha-Sook Chung</td>
<td>Seoul, South Korea</td>
<td></td>
</tr>
<tr>
<td>Larry E. Hartl</td>
<td>CPS, Inc. Westchester, IL</td>
<td></td>
</tr>
<tr>
<td>Anand K. Yadav</td>
<td>Fort Valley State U. Fort Valley, GA</td>
<td></td>
</tr>
<tr>
<td>Taro Amagata</td>
<td>Grafton, MA</td>
<td></td>
</tr>
<tr>
<td>Michael Fantuzzi</td>
<td>Soft Gel Tech., Inc. Glendale, CA</td>
<td></td>
</tr>
<tr>
<td>Nirmal Joshee</td>
<td>Fort Valley State U. Fort Valley, GA</td>
<td></td>
</tr>
<tr>
<td>Bei Jiang</td>
<td>Columbia Univ. Flushing, NY</td>
<td></td>
</tr>
<tr>
<td>Krishna Kumar</td>
<td>Howard University Washington, DC</td>
<td></td>
</tr>
<tr>
<td>Paul F. Long</td>
<td>Univ. of London London, UK</td>
<td></td>
</tr>
<tr>
<td>Maha A. Aboul Ela</td>
<td>Alexandria Univ. Alexandria, Egypt</td>
<td></td>
</tr>
<tr>
<td>Lin Hongxiang</td>
<td>Tianjin, P.R. China</td>
<td></td>
</tr>
<tr>
<td>Chong-Zhi Wang</td>
<td>Univ. of Chicago Chicago, IL</td>
<td></td>
</tr>
<tr>
<td>Jurgen Rohr</td>
<td>Univ. of Kentucky Lexington, KY</td>
<td></td>
</tr>
<tr>
<td>Sohail Malik</td>
<td>Univ. of Georgia Athens, GA</td>
<td></td>
</tr>
<tr>
<td>Zhihong Song</td>
<td>Texas Tech Univ. Lubbock, TX</td>
<td></td>
</tr>
<tr>
<td>Jim Z. Wang</td>
<td>U. of IL at Chicago Chicago, IL</td>
<td></td>
</tr>
<tr>
<td>P. D'mello</td>
<td>Kandnani., Coll. Pharm Mumbai, India</td>
<td></td>
</tr>
<tr>
<td>Tamara Meragelman</td>
<td>Screen Tech Br., NCI Frederick, MD</td>
<td></td>
</tr>
<tr>
<td>Zhi-xiu Lin</td>
<td>Chinese U. Hong Kong Shatin, Hong Kong</td>
<td></td>
</tr>
<tr>
<td>Gail Payne</td>
<td>Univ. of Newcastle Newcastle upon Tyne, UK</td>
<td></td>
</tr>
<tr>
<td>Robert A. Keyzers</td>
<td>Upper Hutt, New Zealand</td>
<td></td>
</tr>
<tr>
<td>Edith M. Antunes</td>
<td>Rhodes University Grahamstown, South Africa</td>
<td></td>
</tr>
<tr>
<td>Danzil R. Beukes</td>
<td>Rhodes University Grahamstown, South Africa</td>
<td></td>
</tr>
<tr>
<td>Augustine Ahmadu</td>
<td>Ahmadu Bello Univ. Zaria, Nigeria</td>
<td></td>
</tr>
<tr>
<td>Tad A. Turgeon</td>
<td>Nat. Sunshine Prod. Spanish Fork, UT</td>
<td></td>
</tr>
<tr>
<td>Young Chul Park</td>
<td>Harbor Br. Ocean. Inst. Fort Pierce, FL</td>
<td></td>
</tr>
<tr>
<td>Philip G. Williams</td>
<td>Univ. of California La Jolla, CA</td>
<td></td>
</tr>
<tr>
<td>Harald Gross</td>
<td>Oregon State Univ., Corvallis, OR</td>
<td></td>
</tr>
<tr>
<td>Hyun-Ah Jung</td>
<td>Columbus, OH</td>
<td></td>
</tr>
<tr>
<td>Krishna Misra</td>
<td>Allahabad Univ. Jhaiba, India</td>
<td></td>
</tr>
<tr>
<td>Wendy L. Kelly</td>
<td>Harvard Med. Sch. Boston, MA</td>
<td></td>
</tr>
<tr>
<td>Mahmood Reza</td>
<td>Moein</td>
<td></td>
</tr>
<tr>
<td>Janice R. Kane</td>
<td>Oak Ridge, NJ</td>
<td></td>
</tr>
<tr>
<td>Leslie G. West</td>
<td>Kraft Foods Morton Grove, IL</td>
<td></td>
</tr>
<tr>
<td>Karen Lowell</td>
<td>Grinnell, IA</td>
<td></td>
</tr>
<tr>
<td>Mila A. Emerald</td>
<td>London, Ontario Canada</td>
<td></td>
</tr>
<tr>
<td>Masami Ishibashi</td>
<td>Chiba University Chiba, Japan</td>
<td></td>
</tr>
<tr>
<td>Dong Liu</td>
<td>Louisiana State U. Baton Rouge, LA</td>
<td></td>
</tr>
<tr>
<td>Zhijun Liu</td>
<td>Louisiana State Univ. Baton Rouge, LA</td>
<td></td>
</tr>
<tr>
<td>Arul Veerappan</td>
<td>Cornell University New York, NY</td>
<td></td>
</tr>
<tr>
<td>Yuan Zhao</td>
<td>Unigen Pharm., Inc. Lacey, WA</td>
<td></td>
</tr>
<tr>
<td>Ross Zirkle</td>
<td>Martek Biosciences Boulder, CO</td>
<td></td>
</tr>
</tbody>
</table>
ASSOCIATE MEMBERS

Jonel P. Saludes
Univ. of California
Davis, CA

Sarah C. Lievens
Univ. of California
Davis, CA

Russell Williams
Virginia Tech
Christiansburg, VA

Maciuq Alexandre
Copenhagen, Denmark

Nguyen A. Tho
U. Libre de Bruxelles
Bruxelles, Belgium

Ivie Anho
King's College
Daig, UK

Yoichi Takakusagi
Noda, Japan

Suman Sharma
Delhi, India

Maryam Alyousuf
Abu-Dhabi, UAE

Anil K. Pant
G.B. Pant Univ.
Pantnagar, India

Kapil B. Pant
G.B. Pant Univ.
Pantnagar, India

Jesus I. Murillo
La Paz, Mexico

Tulsi Bhandari
Xechem Pharm. LTD
Abuja, Nigeria

C. S. Pandey
G.B. Pant Univ.
Pantnagar, India

Upasana Shah
Xechem Pharm. LTD
Abuja, Nigeria

Damian W. Laird
Univ. of Utah
Salt Lake City, UT

Janet L. Funk
Univ. of Arizona
Tucson, AZ

Roger G. Lintingston
Oregon State Univ.
Corvallis, OR

Andrew S. Lamm
Fort Pierce, FL

Doralyn S. Dalisay
Univ. of California
Davis, CA

Wenwen Ma
Lacey, WA

Rahul Pawar
Univ. of Mississippi
University, MS

Joseph O. Kuti
Fayetteville State U.
Fayetteville, NC

Wayne W. Harding
Univ. of Iowa
Iowa City, IA

Rui Tan
Cancer Res. Inst., ASU
Mesa, AZ

Amy M. Bystrom
Exelixis Plant Sc.
Portland, OR

David M. Shepherd
Univ. of Montana
Missoula, MT

David Lee
Harvard Med. Sch.
Cambridge, MA

Junichi Tanaka
Univ. of Ryukyu
Nishihara, Okinawa
Japan

Uchechukwu Osunkwo
NIPRD, Idu
Abuja, Nigeria

Damaris Osunkwo
Abuja, Nigeria

Adedeji Oianiike
Sheda Sc. & Tech. Cent.
Abuja, Nigeria

Micaela V. Cesario
Aptos, CA

James T. Lyles
Lehman College, CUNY
Bronx, NY

Radhika Kota
Philadelphia, PA

T.J. Harper
Carolina Beach, NC

Gemma O'Donnell
Cent. Pharmacog. Phytoth.
London, UK

Ang Liu
College of Pharm.
Chicago, IL

Raquel Rodriguez-Guzman
Univ. of Mississippi
University, MS

Nazak Ameri
Bellevue, WA

Shixin Deng
U. of IL at Chicago
Chicago, IL

Richie Bhandare
Monroe, LA

Benjamin A. Lien
Univ. of Minnesota
Duluth, MN

Brent J. Yoder
Virginia Tech
Blacksburg, VA

Chen Ding
U of WI-Madison
Middleton, WI

Xiaojun Wu
Louisiana State U.
Baton Rouge, LA

Oliver Grundmann
Univ. of Florida
Gainesville, FL

Tanja Godecke
Freie Univ. Berlin
Berlin, Germany

Wesley E. Smith
Univ. of Montana
Missoula, MT
Dr. Norman R. Farnsworth, Director of the Program for Collaborative Research in the Pharmaceutical Sciences at the University of Illinois at Chicago is an internationally renowned scholar in the field of Pharmacognosy. He has had an extraordinary career in the University of Illinois, College of Pharmacy since 1970.

He received his B.S. and M.S. degrees at the Massachusetts College of Pharmacy. He earned his Ph.D. from the University of Pittsburgh in 1959. As Professor of Pharmacognosy at Pittsburgh, he initiated a Ph.D. program and received his first research funding from National Institutes of Health (NIH) in 1961 to study the cardiovascular properties of Apocynaceae plants. It was at Pittsburgh that he decided, collaborative research was the way to solve “big problems”, when this concept was not in vogue.

In 1970 he moved to the University of Illinois Medical Center, College of Pharmacy as Head of the Department of Pharmacognosy and Pharmacology. In 1982 he became Director of the Program for Collaborative Research in the Pharmaceutical Sciences. Together with Harry Fong, John Pezzuto, Doug Kinghorn, Geoffrey Cordell, Don Waller, Gail Mahady and Doel Soejarto and more recently with Guido Pauli, Judy Bolton, Richard van Breemen and Jim Wang, he put together an interdisciplinary and collaborative research team involving botany, chemistry, pharmacology and biochemistry unequaled in the USA. This team centered their research in the areas of natural contraceptives, ethnobotany, chemoprevention, cancer chemotherapy, malaria, HIV and most recently in the study of botanical dietary supplements for women’s health (estrogen, serotonin, CNS targets).

This team of researchers produced more than 1,000 publications from 1970 to the present time. The research has led to several patents and two natural plant products that are being further studied at National Cancer Institute (NCI). The research program at Illinois has produced more than 80 Ph.D.s and 15 M.S. graduates since 1970.

In 1975, Dr. Norman Farnsworth established NAPRALERT database, the world's largest database on natural products which is an invaluable resource.

He is a honorary member of several societies, including ASP and the International Society of Ethnopharmacology. He is also the editor of NAPRALERT. Additionally, he is a member of Editorial Advisory Boards of several prestigious journals, which includes the Journal of Natural Products and Herbalgram.

At age 75 Norm is going strong and is planning new research ventures to further explore the more than 200,000 species of flowering plants that have never been chemically or biologically researched. He is quite honored to be the first trained pharmacognosist to receive this prestigious ASP Research Achievement Award.

Dr. Farnsworth will be delivering his award address - “A New Paradigm in Pharmacognosy Research- Botanical Dietary Supplements” at the Annual Meeting Banquet in Corvallis, OR.

Norm...the Society is proud of your achievements, congratulations!
His legacy will continue to touch our lives. Dr. Rinehart passed away on Monday, June 13, 2005 at his Urbana home after a long illness.

Rinehart's research led to the development of a procedure involving mutasynthesis to prepare new antibiotics. He also led the chemistry department's marine natural products program that collected samples from the ocean floor in the mangroves off Puerto Rico and from other collection sites around the world.

In 1990, Dr. Rinehart isolated several extracts produced naturally by sea squirts that showed promise as anti-cancer agents. One of the extracts, eceinasciden, has repeatedly worked safely and effectively in animal studies and through three stages of human clinical trials against soft-tissue sarcomas and lung, breast and ovarian cancers. Rinehart identified the substance, also known as ET-743, in his Illinois laboratory; the university licensed the rights to the compound to PharmaMar SA of Spain for production purposes.

Rinehart was elected as a fellow of the American Association for the Advancement of Science in 1980. He was also a Sloan Fellow and Guggenheim Fellow. He received the ASP Research Achievement Award in 1989 and the Ernest Guenther Award in the Chemistry of Natural Products in 1996 from the American Chemical Society.

He was born March 17, 1929, in Chillicothe, MO. He earned a bachelor's degree in chemistry in...
spectrometry equipment at Illinois.

An avid scuba diver, mountaineer and downhill skier, Rinehart served on the editorial boards of several journals, including the Journal of Antibiotics, Journal of Medicinal Chemistry and the Journal of Natural Products. He also served on the Chemistry Advisory Committee of the Walter Reed Army Institute of Research (1971-75), the Chemical and Biological Information Handling Panel of the National Institutes of Health (1969-1974), the Executive Committee of the American Chemical Society’s Division of Organic Chemistry (1968-1970) and President of American Society of Pharmacognosy (1995-96).

1950 from Yale University and a doctorate in chemistry in 1954 from the University of California at Berkeley. In between, he attended a year of college on a Rotary fellowship at the University of Goettingen in Germany. Rinehart joined the University of Illinois faculty as an instructor in organic chemistry in 1954, and retired in August 2000.

Early in his career, Rinehart played a leading role in obtaining the initial funding for state-of-the art mass

Rinehart is survived by his wife, Marlyn, three sons, Kenneth L. Rinehart III, Tucson, Ariz., John Benjamin Rinehart, Cambridge, Mass., & Nicholas Whitstitt Rinehart, Champaign, IL & two grandchildren.

The end of a legend...
Prof. (Dr) Kenneth L. Rinehart, Jr.

...to Dr. Rinehart’s family and friends
At the International Congress on Natural Products Research (ICNPR-2004) Phoenix, AZ, one of the major highlights of the meeting was its opening day satellite symposium - "Classical Pharmacognosy Forum: The Critical Need for Pharmacognosy in Pharmacy Curricula." In this issue we are presenting a summary report of this workshop by Drs. Roy Upton and John Cardellina.

The workshop focused on the challenges associated with preserving classical techniques of botanical pharmacognosy. From the perspectives of the organizers and feedback from many of the more than 150 attendees, the event was a great success and highlighted the importance of classical pharmacognosy techniques for assuring the authenticity and quality of traditional and modern drugs derived from medicinal plants. Some of the pre-eminent pharmacognosists in the Western world participated in this historic event. Hopefully, this will serve as a springboard for future events and initiatives so that training in the classical techniques of pharmacognosy will be maintained in academia and utilized by manufacturers and researchers of both traditional and modern drugs. Following are some highlights from the presentations.

- **The Ebb and Flow of Pharmacognosy: A Historical Perspective**

  The early development of pharmacognosy as a formal discipline was presented by Professor Wolfgang Kubelka, University of Vienna, beginning with the coining of the term “pharmacognosis” in the *Lehrbuch der Materia Medica* of Johann Adam Schmidt in 1811. This was followed by the formal use of the term pharmacognosy in a thesis of C.A. Seydler (1815). Numerous early herbals were presented as examples of early pharmacognostic works, including those of Bock, Brunfels, Dioscorides, and Matthiolus; these works served as primary references for the identification, actions, and applications of virtually thousands of medicines, most of which were derived from higher plants at the time. As highlighted by Professor Kubelka, pharmacognosy has experienced many fluctuations throughout the past 100 plus years.

  In the early 1800s pharmacognosy was described by Schleiden as "the mother of all disciplines of the natural sciences", while in the *Lehrbuch der Pharmakognosie* (1888) of Mueller it was reported that "pharmacognosy has fallen sleep". In more contemporary times, Professor Geoffrey Cordell reported in the *American Druggist* (1987) that "Pharmacognosy is far from dead. It has survived a long, cold winter and is awakening as the most high-tech pharmaceutical science."

  Professor Kubelka provided examples of the changing face of pharmacognosy in numerous advances in medicine from the early use of modern drugs, such as
squill (Urginea maritima), the identification of digitalis by Withering (1785) as the active compound in a traditional herbal formula used by a Scottish herbalist, and the isolation of morphine from the opium poppy (Papaver somniferum) by Sertürner in 1805, to the development of taxol from the Pacific yew (Taxus brevifolia).

Also relevant to the evolution of pharmacognosy is the evolution of drugs; early drugs were primarily based on whole natural product preparations, whereas drug development in the last century has followed the steady progression of chemical isolation, structural elucidation, and development of single agent chemotherapeutics.

The decline of pharmacognosy in the US was outlined by UIC distinguished professor of pharmacognosy, Norman Farnsworth. According to Farnsworth, pharmacognosy was included in the curriculum of every pharmacy school in the U.S. until the late 1940s and has often been considered as "pharmacy's unique contribution to science." Historically, pharmacognosy was described as a "descriptive" science primarily focused on the identification of plant materials used in drug development.

At the time, the primary focus was on botanical, macroscopic, and microscopic characterization of crude drug plants, disciplines typically dropped from today's pharmacy/pharmacognosy curricula, along with information regarding their collection and processing. Botany, vegetable histology, materia medica, and microscopy were a part of the curriculum of early pharmacists and were required throughout their 3 years of study.

Over time, the scope of pharmacognosy evolved, with Flueckiger (1879) stating that "pharmacognosy is the simultaneous application of various scientific disciplines with the object of acquiring knowledge of drugs from every point of view." This view was echoed in 1929 by professor of pharmacognosy Richard Wasicky who noted "Pharmacognosy is a biologic and experimental science...not only microscopic, but chemical, chromatographic, and biologic methods in addition!"

The continued development of modern pharmacognosy paralleled the evolution of modern drug discovery. As emphasis shifted from the botanical to the chemical aspects of drugs, so did the focus of the pharmacognosist, relating more closely to natural products chemistry than pharmacy.

The development of sophisticated analytical methodologies along with the isolation, structural elucidation, and synthesis of compounds caused the techniques of classical botanical pharmacognosy to lose their importance. Simultaneously, pharmacognosy programs were dropped from the training of pharmacists or were transformed into more specialized disciplines such as "medicinal chemistry" or...
"pharmaceutical biology". In many cases, the classic botanical techniques of pharmacognosy were completely eliminated.

Thus, we see the underpinnings of an identity crisis in the field of pharmacognosy that has persisted from the beginning of pharmacognosy to the present day. Dr. Farnsworth predicted that we will never see the return of pharmacognosy in the training of pharmacists, which raises the question—where will pharmacognosy live in academia?

- **Renewed Interest in Classical Botanical Pharmacognosy**

Worldwide there has been a resurgence in the use of traditional herbal drugs and, similarly, a growing interest in scientific investigations of their clinical efficacy and safety. Pharmacognosy, with all of its tools and expertise, plays an integral role in this process, not only for ensuring the authenticity, purity, and consistency of the materials being used and investigated but also for developing biological models for determining efficacy, historically the domain of the pharmacologist.

As pointed out by Prof. Sabine Gläsl, many plants share a similar constituent profile. In many cases, chemistry alone may not be able to discern the identity of the plant to species, at least not in the practical, time-efficient, and cost-effective manner needed for industry. Professor Gläsl provided numerous examples wherein the combination of macroscopic and/or microscopic botanical characterization with thin layer chromatography (TLC) is optimal and, in some cases, superior to more sophisticated chemical analysis alone.

She emphasized that old techniques are not necessarily inferior and may in fact be superior to more modern techniques in speed, cost, and efficiency. It has become clear in the evaluation of botanicals used in the development of supplements and modern drugs that authenticity must be determined using a combination of both physical and chemical tests. While often considered an outdated modality, TLC continues to be used effectively worldwide in the quality and identity assessment of plants.

As a counter-point to Professor Farnsworth's perspective, Professor Hildebert Wagner of Munich made note that paradigm shifts occurring in modern medicine, moving from mono-drug to multi-drug therapies, support a revival of pharmacognosy in the pharmacy curriculum. It has repeatedly been shown that the medicinal activity of many plants is due not to a single constituent or action, but to the myriad of compounds contained within and multiple actions elicited by the botanical. Prof. Wagner suggested that, as modern medicine learns that multi-targeted therapies are more efficacious and oftentimes safer than mono therapies, multi-component herbal drugs may prove to be therapeutically equivalent or superior to individual compounds. Several examples of this were provided, with suggestions for future directions in pharmacognosy to be focused on the multi-component standardization of botanical preparations, elucidation of the total pharmacological profile of botanical using new molecular-biological assays, and the subsequent development of safe and effective plant-based drugs.
Industry Perspectives

Industry perspectives regarding the importance of pharmacognosy to the medicinal plant trade were discussed; it was emphasized that the quality of medicinal plant products is dependent upon the authenticity, growing, harvest, processing, and storage conditions.

It was pointed out that companies must utilize the tools of classical and modern pharmacognosy to appropriately select the plant to be used in the development and regulatory approval of both traditional and modern botanical drugs. This is equally apparent with traditional herbal medicine regulatory models currently in use throughout the European Union and Canada. Training in the complete repertoire of tools and techniques of pharmacognosy, from physical to chemical analysis, is critical in addressing these challenges.

The potential for new drug discovery through biological screening of natural products was discussed, as was the need to integrate the knowledge and skills of classical botanical pharmacognosy with the biological assessment of herbal drugs that are the subject of clinical trials.

Botanical Pharmacognosy...

The Future?

In an attempt to bring closure to the day’s discussions a number of breakout sessions were held to advance ideas for how botanical pharmacognosy would be preserved. Topics of discussion included Educational Needs, Research Tools and Training, and Role in Clinical Research & Standard Setting.

It is clear that the skills and multiple tools of pharmacognosy are needed in the development of modern and traditional drugs derived from natural products. What is not clear is where and how pharmacognosy should reside academically. Some thought that perhaps specialization in botanical pharmacognosy should occur as postgraduate training rather than at the graduate level. However, this was countered by those who felt that some of the basic skills of botanical quality control were needed at the undergraduate level, offering a better avenue to career paths in the botanical products industry or botanical medicine research.

“...note that paradigm shifts occurring in modern medicine, moving from mono-drug to multi-drug therapies, support a revival of pharmacognosy in the pharmacy curriculum...”

Regarding clinical needs, it is clear that those conducting botanical medicine research need to have accurately characterized the products being studied in
order to foster experimental reproducibility. This has been highlighted by the National Center for Complementary and Alternative Medicine (NCCAM), which requires this of potential recipients of NCCAM funds. Similar requirements should be made of journals reporting on botanical medicine studies, so that similarly reproducible experiments may be conducted and so an accurate assessment of the findings of the study can be made. Such requirements already exist at the Journal of Natural Products and Planta Medica.

Regarding research tools and training, it was noted that students are not aware that industry needs include the development and validation of analytical methods for the measurement of marker compounds in herbal ingredients and products. Neither are they aware that the development of simple biological assays can be of great benefit to supplement companies wanting to validate some level of safety and efficacy of their products. It could also be said that most of industry is not aware of the valuable roles pharmacognosists can play in both of these areas. A potential solution for this mutual lack of understanding was the development of industry internships that could be used to orient students to industry needs. This would make them more marketable to industry and would be potentially grantable. Additionally it was noted that industry has a lot of experience to offer to those academic institutes with a consistent interest in the study of botanical products.

Lastly, the tools of botanical pharmacognosy are integral to the development of quality control, regulatory, and pharmacopoeial standards. Compliance with national and international standards requires both physical and chemical characterization of botanicals; in many cases neither will suffice alone. The conclusion of the participants in these forums was, “there was not enough time!”

**Conclusion**

There is no doubt as to the value of the modern pharmacognosist in the development of modern drugs and herbal products and the continued evolution of molecular biology. However, the resurgence in the use of traditional herbal drugs worldwide suggests a need for preservation and continued training in the classic techniques, whereby the physical tests of early pharmacognosists can be coupled with the chemical sophistication of modern pharmacognosy and biological screening methodologies.

The primary question raised in this forum was not whether the tools of classical pharmacognosy have value (clearly they do), but rather how will the classic tools of botanical pharmacognosy be maintained and in what academic curriculum will these reside; botany, biology, chemistry, nutritional sciences, herbal medicine, pharmacognosy? For now, this remains a question with many potential answers; hopefully, this symposium laid the foundation for further exploration of this important issue. Perhaps the most fitting summary for this report is the following, written by Thomas Edward Wallis, author of Textbook of Pharmacognosy (1946) in a letter to professor of pharmacognosy E.J. Shellard in 1956:

"Pharmacognosy is the most liberal & humanistic of all pharmaceutical studies and should be preserved at all costs. Emphasis is changing but that does not mean that the subject is disappearing."

The Authors
- Roy Upton, Herbalist & Exec. Director, American Herbal Pharmacopoeia
- Dr. John Cardellina, Screening Technologies Branch, National Cancer Institute
ASP Research Achievement Award - 2007

The American Society of Pharmacognosy selects annually a recipient for the ASP Research Achievement Award. Candidates must be members of the Society who have made outstanding contributions to research on natural products. The award consists of an honorarium of $2,500 and travel expenses to present the award lecture at an annual meeting of the Society.

Previous winners are:
1985 - Koji Nakanishi
1988 - Heinz G. Floss
1989 - (Late) Kenneth L. Rinehart, Jr.
1990 - (Late) Monroe E. Wall
1991 - (Late) S. William Pelletier
1992 - (Late) Henry Rapoport
1993 - A. Ian Scott
1994 - (Late) Paul J. Scheuer
1995 - George Robert Pettit
1996 - Meinhart H. Zenk
1997 - John W. Daly
1998 - Sidney Hecht
1999 - David G. I. Kingston
2000 - C. Richard Hutchinson
2001 - Tom Mabry
2002 - Richard Moore
2003 - (Late) D. John Faulkner
2004 - Jon C. Clardy
2005 - Norman R. Farnsworth

Call for Nominations for 2007

Nominations cut off date will be sometime in the Spring of 2006. The exact date will be announced in the Fall 2005 issue of the ASP Newsletter. Nominations may be sent to the Chairman of the Research Achievement Award Committee and should consist of a nominating letter, a curriculum vitae of the candidate, and letters from three individuals who are familiar with the candidate’s scientific accomplishments.

Nomination documents should be submitted in triplicate to:

Dr. James Gloer
Department of Chemistry
University of Iowa
Iowa City, Iowa 52442
Phone: 319-335-1361
Fax: 319-335-1270
james-gloer@uiowa.edu

ASP – Employment Service

The Society offers a placement service to aid our members in seeking positions or employees. This service is available to ASP members and is free to both the applicant and the prospective employer. The following services are available:

(1) Prospective employers can have positions posted for free at the ASP Employment site [http://www.phcog.org/positions.html]. The ad is typically 300 words or less, and should include appropriate contact information. Ads should be sent to Ed Kennelly as attached files (Microsoft Word is the preferred format). You may also send a logo to be included in the ad. Ads can often be posted within 2-3 business days.
(2) When the ASP Employment website is updated, members can be notified by e-mail if they so desire.
(3) ASP members can send resumes to Ed Kennelly. Resumes should be 1-4 pages, and may be submitted electronically as attached files either as Microsoft Word document or as a PDF file. Resumes will remain on file for one (1) year, at which time it will be deleted. All information submitted will be held in strict confidence.
(4) ASP Employment Service will share resumes with prospective employers.

For further information, contact:

Edward J. Kennelly, Ph.D.
Department of Biological Sciences
Lehman College, City Univ. of New York
250 Bedford Park Blvd. W., Bronx, NY 10468
Tel: 718-960-1105; Fax: 718-960-8236
E-mail: kennelly@lehman.cuny.edu

Visit the ASP Job Service Website at: [www.phcog.org/employment.html]
New & Noteworthy

Journal of Natural Products....
Search for Volunteers for Book Reviews

One of the challenges a book review editor faces is identifying capable and interested referees for certain books. The Journal of Natural Products seeks to review books encompassing a broad range of topics directly related to natural products or potentially impacting the field of natural products. It is relatively easy to identify appropriate reviewers for most books in the mainstream of natural products— Isolation, identification, chemistry, and biological activity. However, as books move out from that mainstream area or become very specialized, it is less intuitively obvious to the current book review editor whom to recruit for such reviews.

This message is being sent out in the hope that volunteers may rush forward or at least tentatively indicate their potential interest and willingness to review books listed at the ASP website for those books that the book review editor has had difficulty ‘placing’ for review. The book review editor will happily accept volunteers who are interested and willing to review one of the listed books. The editor will also be glad to receive suggestions from browsing members who know an expert appropriate for one of the books listed. A good review of a book related to natural products is a service both to the American Society of Pharmacognosy and to all the readers of the Journal of Natural Products.

Books available for review will be listed at the ASP website:
(www.phcog.org) under New & Noteworthy

Herbal Extract May Help Curb Obesity

With the incidence of obesity drastically rising, we need more safe & effective weight-loss products...

An Ayurvedic herb, Coleus forskohlii, is a member of the mint family (Lamiaceae) and native to the subtropical regions of India, Myanmar and Thailand. It is a spice and medicinal herb with a long history of usage in Ayurvedic medicine. The root of this “power” herb contains the highest levels of the active ingredient, forskolin. Coleus forskohlii has shown promise at improving body composition, according to Indian scientists.

Forslean is a patented form of Coleus Forskohlii. It is considered effective in weight loss due to the main ingredient, forskolin. Forskolin is important because of its ability to activate the enzyme, Adenylyl Cyclase. This enzyme is involved in the metabolism of cyclic adenosine monophosphate (cAMP). cAMP is involved in many other metabolic and thermogenesis process, one of which is the burning of fat.

A 12 week double-blind, randomized study funded by Sabinsa showed that volunteers who took 250 mg of ForsLean lost an average of 4% of their total body weight. ForsLean has been studied and independently tested in several clinical trials. Results show an overall trend to decrease body weight and fat content while maintaining or increasing lean body mass. ForsLean has been shown to be safe and effective at levels of up to 500 mg per day.
MEETINGS

A  Future ASP Meetings

2005 -  
46th Annual ASP Meeting  
*July 23-27, Corvallis, Oregon*

2006 -  
47th Annual ASP Meeting  
*July 22-26, Crystal City, Virginia*

2007 -  
48th Annual ASP Meeting  
*July 14-18, Portland, Maine*

2008 -  
International Congress in Athens, Greece  
*Dates to be Announced*

2009 -  
ASP 50th Anniversary...Golden Jubilee  
*June 27- July 1, Honolulu, Hawaii*

B  Other Meetings of Interest

-Aug. 15-18, 2005, University, MS  
*International Conference Quality & Safety Issues Related to Botanicals*

-For more information contact:  
-Ikhas Khan, Ph.D.  
-Tel: 662-915-7821; Fax: 662-915-1006  
-Email: khan@olemiss.edu

-Aug. 19-21, 2005, Edison, NJ  
*International Conference on Catalyzing the Globalization of Integrated Healthcare Systems*

-For more information visit:  
-www.inhex.com

-Dec 15 - 20, 2005 -- Honolulu, Hawaii  
*PACIFICHEN...2005*

-For more info visit:  
-www.pacificchem.org

-July 25-29, 2006 -- Bethesda, MD  
*4th International Conf. on Countercurrent Chromatography (CCC-2006)*  
*One-day Comprehensive symposium on - CCC, July 27, 2006; Free of charge*

-For more details contact:  
-Yoichiro Ito, M.D.  
-Center for Biochem. & Biophysics, NHLBI, NIH  
-Bldg. 50, # 3334, 50 South Dr., Bethesda, MD 20892  
-Tel: 301-496-1210; Fax: 301-402-3404  
-Email: itoy@nhlbi.nih.gov

DID YOU KNOW?

☐ That...Omega-3 Claims Approved for foods?

FDA in September 2004 finally approved a qualified health claim for a reduced risk of coronary heart disease (CHD) on conventional foods that contain eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) omega-3 fatty acids. This was done by the agency to improve consumers’ understanding of the health benefits of omega 3 fatty acids in oily fish such as salmon, lake trout, tuna and herring.

FDA said while these fatty acids are not essential to the diet, scientific evidence indicates that they may be beneficial in reducing CHD. As this research is not conclusive, FDA intends to exercise its enforcement discretion with respect to the following qualified health claim: "Supportive but not conclusive research shows that consumption of EPA and DHA omega-3 fatty acids may reduce the risk of coronary heart disease. One serving of [name of food] provides [x] grams of EPA and DHA omega-3 fatty acids."

☐ That...Tart Cherry Extract Shows Promise for Pain Control?

Tart cherries have been credited in unscientific reports as reducing pain from gout and arthritis. To investigate this possibility, Dr. Jill M. Tall, Johns Hopkins Hospital, directed experiments (at Hopkins and Michigan State University) with rats using tart cherry extracts called anthocyanins, pigments that color flowers and fruits from blue to red. Earlier laboratory research had already shown that anthocyanins had strong anti-inflammatory properties.

However, until this study, no research had been done with animals. This research found that anthocyanins given by mouth reduced pain and swelling related to inflammation as effectively as a medicine commonly used to treat pain and swelling. For more details see: Behavioural Brain Research (August 12, 2004).
**ASP Member Honored**

**Hameed Khan Receives 2004 - NIH Scientific Achievement Award**

Dr. Hameed Khan, a Health Scientist at the National Institute of Child Health and Human Development (NICHD), at the National Institutes of Health (NIH) received the prestigious 2004 - NIH Scientific Achievement Award for the Discovery of an experimental Cancer Drug.

This award was presented to him by Dr. Elias Zherhouni, the Director of NIH, Bethesda, MD, during the NIH-APAO Award Ceremony on December 3, 2004, for the discovery of Aziridinyl Benzoquinone (AZQ) (US Patent 4,146,622), a Novel experimental drug specifically designed to shut off gene that causes Brain Cancer (Malignant Glioma). Benzoquinone group helps to carry Aziridinyl group across the Blood Brain Barrier and the Aziridinyl group attacks the DNA of the Malignant Glioma cells inhibiting tumor growth.

Dr. Khan was also rewarded with a 17-year royalty for this invention (License Number 1-019-91/0). To this date, more than 250 research papers have been published on AZQ.

---

**News Alert**

**DHEA May Pose Prostate Cancer Risk**

Dehydroepiandrostosterone (DHEA) is a hormone that occurs naturally in the body. Levels decrease as people age. Some people take DHEA as a dietary supplement with the hope of slowing down the aging process.

However, previous research on DHEA provided conflicting results about whether the hormone protects against or increases the risk of certain cancers.

In the March 2005 issue of the American Journal of Physiology--Endocrinology and Metabolism, Julia Arnold, Ph.D., and a team of researchers at NCCAM described experiments conducted on DHEA and prostate cancer cells. The experiments indicated that DHEA, like other naturally occurring hormones, may cause prostate cancer cells to grow.

Until more research is completed, the researchers cautioned that men who have or may have prostate cancer should avoid taking DHEA supplements.
**News For Researchers**

**A** NCCAM Launches New Strategic Plan

The National Center for Complementary and Alternative Medicine (NCCAM) has released its new five-year strategic plan, "Expanding Horizons of Health Care: Strategic Plan 2005-2009," charting the center’s goals and objectives for the next five years.

The plan was developed by reviewing NCCAM’s past accomplishments & challenges the center faces. Further, several goals and objectives presented in the strategic plan were a direct reflection of the lessons learned over the last five years, public input, the advice of NCCAM staff & the recommendations of a distinguished group of outside experts. During the year-long process of development, hundreds of people testified at regional meetings, provided comments in letters and e-mails, and responded to the draft plan on the NCCAM website. The plan addresses four key areas...

- Investing in research
- Training CAM investigators
- Expanding outreach and
- Advancing the organization

The plan sets ambitious goals in various areas of CAM practices. In the new plan NCCAM pointed out the need for better quality control of the herbal/botanical products studied and the importance of conducting research to identify optimal doses and appropriate subject populations before investing in large clinical trials.

For details visit: nccam.nih.gov/about/plans/2005

---

**B** NCCAM & ODS Announced Five New Botanical Centers

NCCAM & ODS of NIH recently announced to fund five new university-based research centers that will focus on botanicals (plants & their product), including identification of their active phytochemical constituent, mechanism of action, safety, effectiveness and quality control. The five centers that will receive the funds are:

- **Botanical Center for Age-Related Diseases: Connie Weaver, Ph.D. (PI)**
  - Partner Institutions: Purdue Univ., West Lafayette, IN; Univ. of AL at Birmingham; Rutgers Univ., NB, NJ
  - To Study: the health effects of polyphenols from soy and kudzu for their potential to prevent and treat osteoporosis, cognitive decline, cataracts and other diseases etc.

- **Botanical Dietary Supplements for Women's Health: Norman Farnsworth, Ph.D. (PI)**
  - Institution: University of Illinois at Chicago.
  - To Study: herbal supplements, that may have benefits for women’s health, such as black cohosh and red clover for menopausal symptoms. In addition, research training will be supported.

- **Botanicals and Metabolic Syndrome: William Cefalu, M.D. (PI)**
  - To Study: the effects of herbal extracts (Russian tarragon, Shilianhua, and grape) on metabolic syndrome.

- **MSKCC Res. Center for Bot. Immunomodulators: Drs. Barrie Cassileth & Philip Livingston (PIs)**
  - Partner Institutions: Mem. Sloan-Kettering Cancer Center, NY; Weil Med. Coll. of Cornell University, NY; The Rockefeller Univ., NY; Inst. of Chinese Med. & Chinese Univ., Hong Kong, China
  - To Study: botanicals that may affect immune function—echinacea, maifanite, astragalus, turmeric, & a traditional Chinese formula

- **Wake Forest and Harvard Center for Botanical Lipids: Floyd Chilton, Ph.D. (PI)**
  - Partner Institutions: Wake Forest Univ., Winston-Salem, NC; Harvard Univ., Cambridge, MA
  - To Study: polyunsaturated fatty acids derived from botanicals, such as flaxseed, echium, and borage, for their anti-inflammatory actions to treat diseases such as atherosclerosis & asthma.
MEMBERSHIP
Membership in the American Society of Pharmacognosy is recognized in several categories.

Full Membership
Full membership is open to any scientist interested in the study of natural products. Dues are $35.00 per year. In order to receive the Journal of Natural Products the subscription rates are as follows: United States, Canada, and Mexico: $114 (Print Edition), $60 (Web Edition), $120 (Archive Web Edition); All other countries: $170 (Print edition), $60 (Web edition), $120 (Archive Web Edition).

Associate Membership
Associate membership is open to students of pharmacognosy and allied fields only. These members are not accorded voting privileges. Dues are $20.00 per year. In order to receive the Journal of Natural Products the subscription rates are as follows: United States, Canada, and Mexico: $86 (Print Edition), $60 (Web Edition), $120 (Archive Web Edition); All other countries: $142 (Print Edition), $60 (Web Edition), $120 (Archive Web Edition).

Emeritus Membership
Emeritus membership is open to retired members of the Society who maintained membership in the Society for at least five years. Dues are $3.00 per year. These members receive the ASP Newsletter. Emeritus members may subscribe to the Journal of Natural Products at the Full Member rates.

Honorary Membership
Honorary members are selected by the Executive Committee of the American Society of Pharmacognosy on the basis of meritorious service to pharmacognosy.

Present Honorary Members are:
- Dr. Arnold Brossi, National Institutes of Health (NIH), MD • Dr. David P. Carew, Univ. of Iowa, IA
- Dr. Gordon C. Cragg, National Cancer Institute (NCI), NIH, MD
- Dr. Norman R. Farnsworth, Univ. of IL at Chicago, IL • Dr. R. Hegnauer, Leiden, Netherlands
- Dr. Albert Hofmann, Switzerland • Dr. Harry H. S. Fong, University of Illinois, IL
- Dr. James E. Robbers, Purdue Univ., IN • Dr. Mansukh Wani, Research Triangle Institute, NC
- Dr. E. John Staba, Univ. of Minnesota, MN • Dr. Hildebert Wagner, Univ. of Munich, Germany
- Dr. David J. Slatkin, Chicago State University, IL

Additional information about membership may be obtained by writing to the Treasurer of the Society:
David J. Slatkin, Ph.D, Treasurer, The American Society of Pharmacognosy, 3149 Dundee Road, #260, Northbrook, Illinois 60062. Email: asphcog@aol.com

ASP Newsletter
Renuka Misra, Ph.D, Editor
Hemantha Jilella, Assistant Editor
Deadlines for submission of articles are as follows:
Spring Issue ...March 1st
Summer Issue......June 1st
Fall Issue........September 1st
Winter Issue......December 1st
Send information to:
Renuka Misra, Ph.D
Editor -- ASP Newsletter
NIA/NIH & Xchem
12106 Pawnee Drive
Gaithersburg, MD 20878
Tel/Fax: (301) 330-5098
Email: renuasp2002@yahoo.com